Phase I Trial of Anti-Gd2 Monoclonal Antibody Hu3F8 Plus GM-CSF: Impact of Body Weight, Immunogenicity and Anti-Gd2 Response on Pharmacokinetics and Survival
OncoImmunology - United States
doi 10.1080/2162402x.2017.1358331
Full Text
Open PDFAbstract
Available in full text
Date
July 31, 2017
Authors
Publisher
Informa UK Limited